Numerai’s NovoCure NVCR Stock Holding History

Numerai’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.17M	Buy	76,901 +49,975	+186%	+$756K	0.1%	359
2026 Q1	$293K	Sell	26,926 -24,292	-47%	-$303K	0.03%	655
2025 Q4	$662K	Buy	+51,218	New	+$657K	0.08%	341

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Numerai's NVCR Position: Q2 2026 in Review

Numerai increased its NovoCure (NVCR) stake by 186% in Q2 2026, buying an estimated $756K and bringing the position to 76,901 shares worth $1.17M. The position accounts for 0.1% of the portfolio, ranked #359.

Numerai first reported a position in NVCR in Q4 2025 and has held it in 3 quarters since. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Numerai held 76,901 shares of NovoCure worth $1.17M as of Q2 2026.
Numerai bought 49,975 NovoCure shares in Q2 2026, an estimated $756K.
NovoCure made up 0.1% of Numerai's portfolio in Q2 2026, its #359 holding.
Numerai first reported a position in NovoCure in Q4 2025 and has held it in 3 quarters since.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Numerai's 13F filing for Q2 2026, filed 14 Aug 2026.